Organon and Gene Logic enter collaboration to find new therapeutic applications for clinical drug candidates
Gene Logic Inc. and Organon announced that they have entered into a drug repositioning agreement to seek alternative development paths for multiple drug candidates of which Organon has previously discontinued clinical development.
Under the terms of the agreement, Gene Logic will seek new therapeutic uses for Organon compounds. Upon discovery of potential new therapeutic utility, both companies will become equal owners and may decide to jointly develop and commercialize the drug candidate. Gene Logic will receive a success-based milestone payment for each therapeutic candidate that Organon chooses to enter into clinical development.
Gene Logic's Drug Repositioning Program seeks to find alternative development paths for drug candidates with good safety records that have been deprioritized or discontinued in Phase II or Phase III clinical trials. The program offers pharmaceutical partners a novel approach to bolster their late-stage pipelines with safe, high-quality drug candidates that originated from their own R&D efforts. Applying a diverse set of drug discovery technologies in parallel, Gene Logic's Drug Repositioning Program evaluates drug candidates for potential utility across a wide spectrum of disease indications.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
